Eris Lifesciences share price
NSE: ERISBSE: 540596Pharmaceuticals & BiotechnologySmall Cap
Last close ₹1,095.50down ₹25.70 (2.29%)BSE ₹1,097.65
Share price at the NSE close on 23 Oct 2026. Previous close ₹1,121.20.
52-week range of traded prices to 23 Oct 2026
₹1,087.90Low, 23 Oct 2026₹1,740.00High, 9 Dec 2025
- Next results date: the board meets on 26 Oct 2026 to consider: financial results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹15,199 Cr353rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 29 Jul 2026
- 23.6
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 20 May 2026
- 3.9
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.66%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 29 Jul 2026
- 19.1%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 29 Jul 2026
- 13.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 20 May 2026
- 0.59
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 37,94348.8% delivered
Results
Consolidated; ₹ crore, the charts by years to March, the table by quarter.Quarterly results
Quarter to Jun 2026, against the quarter beforeFiled 29 Jul
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹873 Crup 15.42%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹143 Crdown 48.65%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax.
- 16.4%
Revenue by year
Peak revenue ₹3,129 Cr, year to Mar 2026
Net profit by year, a loss in red
| ₹ crore | Sep 2024Filed 28 Oct | Dec 2024Filed 5 Feb | Mar 2025Filed 12 Jun | Jun 2025Filed 5 Aug | Sep 2025Filed 12 Nov | Dec 2025Filed 13 Feb | Mar 2026Filed 20 May | Jun 2026Filed 29 Jul |
|---|---|---|---|---|---|---|---|---|
| Revenue | 739 | 727 | 705 | 773 | 792 | 807 | 757 | 873 |
| Net profit | 96 | 87 | 102 | 125 | 134 | 109 | 279 | 143 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. | 13.0% | 12.0% | 14.5% | 16.2% | 17.0% | 13.5% | 36.9% | 16.4% |
Consolidated. The last eight quarters. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Business segments
In the year to Mar 2026 the company reports one business segment, Pharmaceuticals, which carries all its revenue.
Valuation
Today, against the company's own history.PE ratio and valuation history
Price to earningsPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
At or below today's level on 29% of 2,077 trading days since Jun 2018.
LowestHighest
Its median28.3Industry median28.3
Price to bookPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.
At or below today's level on 1% of 1,974 trading days since Nov 2018.
LowestHighest
Its median5.5Industry median2.8
EV to EBITDAEnterprise value to EBITDA. Market cap plus borrowings less cash and bank balances, divided by operating profit before depreciation (revenue less operating expenses, without other income and one-off items) over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly): what the whole business costs against the profit its operations make. Lease liabilities are not counted: the results filings do not state them.15.3
At or below today's level on 2% of 1,974 trading days since Nov 2018.
LowestHighest
Its median19.9Industry median18.7
Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.
At or below today's level on 67% of 2,291 trading days since Jul 2017.
LowestHighest
Its median0.43%Industry median0.51%
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −7.9% | +75.4% | −47.8% | 0.6% |
| 3 years | +31.7% | +17.3% | +12.0% | 0.4% |
| 5 years | +17.1% | +11.6% | +4.4% | 0.6% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add.
Mutual funds holding it
60 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 11 of the 17 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future. 1 more fund filed its first portfolio on record, holding it.Mutual fund holdings
- Bought for the first timeBought for the first time. Funds that held it at the month's end and had not held it in any month on record before.
- 1
- AddedAdded. Funds that held more shares than at the end of the month before.
- 5
- CutCut. Funds that held fewer shares than at the end of the month before.
- 12
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 41
- Sold outSold out. Funds that held it at the end of the month before and hold none at this month's end.
- 34
| Fund | |||
|---|---|---|---|
 HDFC Small Cap FundHDFC Mutual Fund | 64,64,629 | 1.89% | ₹770.5 Cr |
| HDFC Aggressive Hybrid FundHDFC Mutual Fund | 24,59,629 | 1.39% | ₹293.2 Cr |
 Franklin India Small Cap FundFranklin Templeton Mutual Fund | 23,92,469 | 2.00% | ₹285.2 Cr |
| Franklin India Flexi Cap FundFranklin Templeton Mutual Fund | 14,17,881 | 0.93% | ₹169.0 Cr |
 DSP Small Cap FundDSP Mutual Fund | 12,30,000 | 0.68% | ₹146.6 Cr |
 HSBC Small Cap FundHSBC Mutual Fund | 7,76,897 | 0.50% | ₹92.6 Cr |
 UTI Flexi Cap FundUTI Mutual Fund | 7,21,077 | 0.38% | ₹85.9 Cr |
 Mirae Asset Healthcare FundMirae Asset Mutual Fund | 6,99,590 | 2.39% | ₹83.4 Cr |
| HDFC Multi Cap FundHDFC Mutual Fund | 6,78,362 | 0.41% | ₹80.9 Cr |
| HDFC Large & Mid Cap FundHDFC Mutual Fund | 6,75,000 | 0.28% | ₹80.5 Cr |
Portfolios disclosed for Sep 2026. Weight is the holding as a share of the fund's assets.
Peers and competitors
Pharmaceuticals, 216 listed companies, priced on 23 Oct 2026. The table lists the 8 companies closest to Eris Lifesciences in market cap.
Where the company sits among the companies nearest its size
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
 PfizerPFIZER | 16,525 | 22.5 | 3.9 | 14.2 | +10.7% | −9.1% | 17.5% | 21.0% | 2.08% |
 Natco PharmaNATCOPHARM | 15,534 | 13.6 | – | – | −20.7% | −32.6% | 13.6% | 8.6% | 0.57% |
 Alivus Life SciencesALIVUS | 15,354 | 25.5 | 4.6 | 18.3 | +7.9% | +21.7% | 19.6% | 22.7% | 0.40% |
 Onesource Specialty PharmaONESOURCE | 15,299 | – | 2.6 | 48.6 | +27.2% | – | −0.8% | 0.8% | 0.00% |
 AstraZeneca Pharma IndiaASTRAZEN | 14,971 | 88.3 | 17.2 | 63.2 | +31.1% | −7.5% | 20.6% | 24.4% | 0.60% |
 Jubilant PharmovaJUBLPHARMA | 14,945 | 42.4 | 2.1 | 13.9 | +16.3% | −23.5% | 5.3% | 7.3% | 0.53% |
 Alembic PharmaceuticalsAPLLTD | 14,941 | 21.6 | 2.6 | 13.8 | +14.1% | +14.6% | 12.7% | 11.8% | 1.58% |
 Marksans PharmaMARKSANS | 13,001 | 25.2 | 4.3 | 16.9 | – | – | 17.1% | 19.9% | 0.31% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Dividends
Per share, by the year it was paid for, and the latest payments.Dividend history and dates
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up.Highest ₹7.35 a share, years to Mar 2023 and Mar 2025.
| Ex-date | Type | Per share |
|---|---|---|
| 29 May 2026 | Interim | ₹7.21 |
| 13 Feb 2025 | Interim | ₹7.35 |
| 11 Aug 2022 | Interim | ₹7.35 |
| 5 Aug 2021 | Interim | ₹6.01 |
| 13 Aug 2020 | Interim | ₹5.50 |
| 19 Mar 2020 | Interim | ₹2.87 |
Latest payments, as declared, by ex-date.
Latest announcements
Routine notices left out.Share news and announcements
Oct 2026
19 Oct · Analysts
Sep 2026
Eris Lifesciences share price by year
Each calendar year to 2025.Eris Lifesciences share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 1,505.60 | +9.6% | 1,847.70 | 1,153.10 |
| 2024 | 1,373.70 | +51.0% | 1,522.70 | 831.30 |
| 2023 | 910.00 | +40.6% | 946.45 | 567.95 |
| 2022 | 647.25 | −14.8% | 764.35 | 621.70 |
| 2021 | 760.05 | +31.1% | 836.45 | 569.05 |
| 2020 | 579.95 | +22.4% | 595.15 | 362.15 |
| 2019 | 474.00 | −31.0% | 707.50 | 370.20 |
| 2018 | 687.15 | −13.5% | 826.10 | 589.35 |
| 2017 | 794.35 | – | 802.40 | 528.25 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. 2017 is from its first session, 29 Jun 2017.
Recent sessions
The last 10 trading days to 23 Oct 2026, as traded on NSE.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 23 Oct 2026 | 1,126.60 | 1,126.60 | 1,087.90 | 1,095.50 | 1,102.67 | 37,943 | 48.8% |
| 22 Oct 2026 | 1,128.00 | 1,145.10 | 1,111.60 | 1,121.20 | 1,126.26 | 29,717 | 31.7% |
| 21 Oct 2026 | 1,120.40 | 1,149.90 | 1,112.90 | 1,136.30 | 1,133.71 | 84,960 | 47.4% |
| 19 Oct 2026 | 1,144.40 | 1,148.00 | 1,111.10 | 1,120.40 | 1,129.84 | 28,791 | 44.1% |
| 16 Oct 2026 | 1,144.00 | 1,155.90 | 1,130.60 | 1,144.40 | 1,145.59 | 80,705 | 81.2% |
| 15 Oct 2026 | 1,152.50 | 1,157.60 | 1,143.20 | 1,148.80 | 1,152.41 | 32,768 | 65.2% |
| 14 Oct 2026 | 1,148.90 | 1,165.90 | 1,137.90 | 1,149.60 | 1,153.62 | 23,511 | 36.8% |
| 13 Oct 2026 | 1,155.00 | 1,158.70 | 1,142.20 | 1,149.80 | 1,151.60 | 41,111 | 49.8% |
| 12 Oct 2026 | 1,165.00 | 1,185.50 | 1,150.00 | 1,157.10 | 1,170.14 | 1,89,774 | 82.6% |
| 9 Oct 2026 | 1,155.00 | 1,181.50 | 1,150.00 | 1,170.70 | 1,169.96 | 72,434 | 45.2% |
Prices in ₹ per share as traded, not adjusted.
Company details
- Legal name
- Eris Lifesciences Limited
- NSE symbol
- ERIS
- BSE code
- 540596
- ISIN
- INE406M01024
- Industry
- Pharmaceuticals & Biotechnology
- Listed
- Jun 2017
- Face value
- ₹1
- CIN
- L24232GJ2007PLC049867
- Corporate identity number, the registrar of companies' code for it